AMENDMENT TO THE CLAIMS

This listing of claims will replace all prior versions of claims in the application.

<u>Listing of Claims:</u>

- 1-21 (Cancelled)
- 22. (Previously Presented) An anticancer composition comprising a mixture of an anticancer agent and a calcium phosphate paste, said paste comprised of one or more nanocrystalline or poorly crystalline calcium phosphates and a physiologically acceptable fluid, the paste having an injectable or formable consistency at the time of administration and hardenable at the tumor site.
- 23. (Original) The composition of claim 22, wherein each calcium phosphate has a Ca/P ratio of less than or equal to 1.7.
- 24. (Currently Amended) The composition of claim 22, wherein the anticancer agent is selected from the group consisting of methotrexate, cisplatin, prednisone, hydroxyprogesterone, medroxyprogesterone acetate, megestrol acetate, diethylstilbestrol, testosterone propionate, fluoxymesterone, vinblastine, vincristine, vindesine, daunorubicin, doxorubicin, hydroxyurea, procarbazine, aminoglutethimide, mechlorethamine, cyclophosphamide, melphalan, uracil mustard, chlorambucil, busulfan, carmustine, lomustine, dacarbazine (DTIC, dimethyltriazenomideazolecarboxamide), procarbozine, 5-fluorouracil, cytarabine, cytosine

arabinoside, 6-mercaptopurine, tamoxifen, paclitaxel, etoposide, vinorelbine, gemcitabine, leuprolide, flutamide, goserelin acetate, thioguanine, and [their derivatives and] mixtures thereof.

- 25. (Original) The composition of claim 22, wherein the anticancer composition is of a consistency administrable to the tumor site by cannula or by injection.
- 26. (Original) The composition of claim 22, wherein the nanocrystalline or poorly crystalline calcium phosphate cement comprises a calcium phosphate selected from the group consisting of amorphous calcium phosphate, poorly crystalline apatitic (PCA) calcium phosphates (PCA), dicalcium phosphates, such as dicalcium phosphate dihydrate (DCPD) and dicalcium phosphate anhydrous (DCPA), tricalcium phosphates (TCP), monetite, monocalcium phosphate monohydrate (MCPM), hetpacalcium phosphate, calcium pyrophosphate, calcium metaphosphate, octacalcium phosphates (OCP), hydroxyapatites (HA).
- 27. (Original) The composition of claim 26, wherein at least one of the nanocrystalline or poorly crystalline calcium phosphates is selected from the group consisting of amorphous calcium phosphate and poorly crystalline apatitic calcium phosphate.
- 28. (Original) The composition of claim 22, wherein each of the said one or more nanocrystalline or poorly crystalline calcium phosphates has a calcium to phosphate ratio in the range of 1.3 to 1.67.

- 29. (Original) The composition of claim 22, wherein the nanocrystalline or poorly crystalline calcium phosphate paste has an overall calcium to phosphate ratio in the range of 1.0 to 1.7.
- 30. (Original) The composition of claim 22, wherein the nanocrystalline or poorly crystalline calcium phosphate paste has an overall calcium to phosphate ratio in the range of 1.0 to 1.67.
- 31. (Original) The composition of claim 22, wherein the nanocrystalline or poorly crystalline calcium phosphate paste has an overall calcium to phosphate ratio in the range of 1.40 to 1.65.
- 32. (Original) The composition of claim 22, wherein nanocrystalline or poorly crystalline calcium phosphate paste comprises a physiologically acceptable fluid in an amount sufficient to produce a paste having injectable or formable consistency for at least five minutes.
- 33. (Original) The composition of claim 22, wherein nanocrystalline or poorly crystalline calcium phosphate paste comprises a physiologically acceptable fluid in an amount sufficient to produce a paste having injectable or formable consistency for at least twenty minutes.

- 34. (Original) The composition of claim 22, wherein the nanocrystalline or poorly crystalline calcium phosphate paste is hardenable into an apatitic calcium phosphate.
- 35. (Original) The composition of claim 22, wherein a therapeutically effect amount of anticancer agent is released from the composition for a time greater than one week.
- 36. (Currently Amended) The composition of claim 22, wherein a therapeutically effect amount of anticancer agent is released from the composition for a time greater than two weeks [week].
- 37. (Original) The composition of claim 22, wherein a therapeutically effect amount of anticancer agent is released from the composition for a time greater than one month.
- 38. (Original) The composition of claim 22, wherein a therapeutically effect amount of anticancer agent is released from the composition for a time greater than three months.
- 39. (Original) The composition of claim 22, wherein delivery of the anticancer therapy to the tumor site is sufficient to at least prevent increase of tumor mass without significant weight loss of the mammal.
- 40. (Previously Presented) The composition of claim 22, wherein delivery of the anticancer therapy to the tumor site is sufficient to promote a decrease in tumor mass without

significant weight loss in the mammal.

- 41. (Original) The composition of claim 22, wherein the particle size of the calcium phosphate is selected to provide a desired release kinetic of the anticancer drug.
- 42. (Previously Presented) A kit for use in preparing a flowable anticancer composition that remains injectable for at least about 20 minutes, said kit comprising:
- (a) dry ingredients comprising a nanocrystalline or poorly crystalline calcium phosphate and a second calcium phosphate in a proportion of about 1:10 to 10:1 by weight;
- (b) a physiologically acceptable aqueous lubricant in an amount sufficient to produce a flowable product upon combination with said dry ingredients; and
- (c) an anticancer agent in an amount ranging from about 0.01 to 10 wt. % of said dry ingredients.
- 43. (Original) The kit of claim 42, further comprising a means of mixing the dry ingredients and the lubricant.
 - 44. (Original) The kit of claim 42, further comprising injecting means.